Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRTE7A2-01 TCR-T for HPV16+ Advanced Cancers
NCT05122221Phase 1Unknown
- Sponsor
- CorreGene
- Start
- Jul 2022
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CRTE7A2-01 in Cervical Cancer (CC), anal cancer and head and neck cancer (HNC), sponsored by CorreGene. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose Limiting Toxicity at 28 days and 2 more. Status: unknown.
02
Drugs
CRTE7A2-01
03
Conditions
Cervical Cancer (CC)anal cancerhead and neck cancer (HNC)
Beyond the preview
Go deeper on NCT05122221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05122221.